Conference Coverage

This channel highlights DAIC's coverage of numerous key cardiology and medical imaging conferences each year. These include ACC, AHA, ASE, ASNC, EuroPCR, ECR, HIMSS, HRS, RSNA, SCAI, SCCT, TCT, and VIVA.

A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis

News | SPECT-CT

Novel Radiotracer Produces High Quality Images of “Alzheimer’s Disease of the Heart”

June 11, 2024 — A newly developed radiotracer can generate high quality and readily interpretable images of cardiac ...

June 11, 2024

A Review of the 2024 Heart Rhythm Society Conference

Feature | HRS | By Lars Thording, PhD

HRS 2024: Innovation Meets Reality

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient ...

June 11, 2024

New expert consensus from the Society of Cardiovascular Computed Tomography (SCCT) reviews previously published qualitative and semi-quantitative measurements

News | Cardiac Imaging

New Expert Consensus Turns Cardiac CT Imaging into Measurable Standards

June 10, 2024 — New expert consensus from the Society of Cardiovascular Computed Tomography (SCCT) reviews previously ...

June 10, 2024

Xylitol is a common zero-calorie sweetener found in sugar-free candy and toothpaste

News | Hypertension

Study: Young Athletes at Risk for Elevated Blood Pressure Rates, Future Cardiovascular Complications

June 6, 2024 — A substantial portion of young athletes are at risk of hypertension, according to a study presented at ...

June 06, 2024

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

News | Pharmaceuticals

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

June 05, 2024

The 35th Annual ASE Scientific Sessions, will be held June 14-16, at the Oregon Convention Center in Portland, OR, with an expansive program focused on “Global Echocardiography: Innovations in Diagnosis and Beyond.”

Feature | ASE | Christine Book

American Society of Echocardiography Scientific Sessions ASE 2024 Program Highlights

June 4, 2024 — The countdown has begun ahead of the American Society of Echocardiography 35th Annual ASE Scientific ...

June 04, 2024

DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months

News | Cardiovascular Clinical Studies

Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES

June 3, 2024 — Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease ...

June 03, 2024

Conference focuses on rapidly expanding field of sports cardiology and increasing demand for CV care teams who care for athletes

News | Cardiovascular Education

American College of Cardiology Announces Care of the Athletic Heart

May 31, 2024 — In the United States there are over 8 million active athletes. Given the rapid expansion of sports ...

May 31, 2024

Elixir Medical recently announced that the PINNACLE I study, evaluating the safety and performance of its LithiX Hertz Contact Intravascular Lithotripsy System (IVL) met its primary safety and effectiveness endpoint of clinical success. Shown here: Elixir Medical CEO Motasim Sirhan.

News | EuroPCR

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

May 30, 2024 — Elixir Medical, a developer of technologies to treat cardiovascular and peripheral disease, announced ...

May 30, 2024

Data was presented today byAstraZeneca, at the European Atherosclerosis Society (EAS) Congress in France,on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL-C reduction on top of statin in Phase I trial.

News | Cardiovascular Clinical Studies

Oral PCSK9 Inhibitor Demonstrated Significant LDL-C Reduction on Top of Statin in Phase I Trial Presented at EAS Congress

May 29, 2024 — Data was presented by AstraZeneca on AZD0780, an oral PCSK9 inhibitor which demonstrated significant LDL ...

May 29, 2024

Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented at Heart Failure 2024

News | Heart Failure

Heart Failure Patients Who Do Yoga Have Stronger Hearts and Can be More Active

May 28, 2024 — Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with ...

May 28, 2024

The American Heart Association has issued a statement warning that false information about COVID vaccination and heart defects attributed to the Association may be spreading.

News | AHA

American Heart Association Warns of Misinformation Connecting COVID Vaccination to Heart Defects

May 24, 2024 — The American Heart Association has issued a statement warning that false information about COVID ...

May 24, 2024

News | Pharmaceuticals

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

May 24, 2024

Stereotaxis will present an innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablation therapy in underserved regions of Africa

News | EP Lab

Stereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of Africa

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

May 21, 2024

$Early Cardiac Resynchronization Therapy (CRT) may slow the progression of heart failure in patients with mild to moderately reduced left ventricular ejection fraction (LVEF) and left bundle branch block (LBBB), according to a study conducted by a research team led by Yong-Mei Cha, MD, cardiac electrophysiologist at Mayo Clinic, Rochester, MN, presented during the Heart Rhythm Society meeting, HRS 2024.$

News | HRS

Clinical Trial Presented at HRS 2024 Shows Benefits of Early Cardiac Resynchronization Therapy (CRT) in Slowing Progression of Heart Failure

May 19, 2024 — A physician-initiated prospective, randomized clinical trial sponsored by the National Heart, Lung, and ...

May 18, 2024